These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35508695)

  • 1. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
    Miyazaki Y; Kiguchi T; Sato S; Usuki K; Ishiyama K; Ito Y; Suzuki T; Taguchi J; Chiba S; Dobashi N; Tomita A; Harada H; Handa H; Horiike S; Maeda T; Matsuda M; Ichikawa M; Hata T; Honda S; Iyama S; Suzushima H; Moriuchi Y; Kurokawa T; Yokota K; Ohtake S; Yamauchi T; Matsumura I; Kiyoi H; Naoe T;
    Int J Hematol; 2022 Aug; 116(2):228-238. PubMed ID: 35508695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.
    Seymour JF; Fenaux P; Silverman LR; Mufti GJ; Hellström-Lindberg E; Santini V; List AF; Gore SD; Backstrom J; McKenzie D; Beach CL
    Crit Rev Oncol Hematol; 2010 Dec; 76(3):218-27. PubMed ID: 20451404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
    Santini V; Fenaux P; Mufti GJ; Hellström-Lindberg E; Silverman LR; List A; Gore SD; Seymour JF; Backstrom J; Beach CL
    Eur J Haematol; 2010 Aug; 85(2):130-8. PubMed ID: 20394651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine.
    Ogawa S; Sakamoto T; Matsuoka R; Ishitsuka K; Ogino Y; Sootome A; Makishima K; Yoshida C; Ito Y; Shimizu S; Suyama T; Shinagawa A; Ito T; Obara N; Kusakabe M; Sakata-Yanagimoto M; Miyazaki Y; Nannya Y; Chiba S
    Cancer Rep (Hoboken); 2024 Jan; 7(1):e1938. PubMed ID: 38014499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
    Zeidan AM; Mearns ES; Ng CD; Shah A; Lamarre N; Yellow-Duke A; Alrawashdh N; Yang B; Cheng WH; Bui CN; Svensson A
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):177-186. PubMed ID: 37996264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
    Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
    J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
    Fenaux P; Gattermann N; Seymour JF; Hellström-Lindberg E; Mufti GJ; Duehrsen U; Gore SD; Ramos F; Beyne-Rauzy O; List A; McKenzie D; Backstrom J; Beach CL
    Br J Haematol; 2010 Apr; 149(2):244-9. PubMed ID: 20136825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
    García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
    Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.
    Xicoy B; Jiménez MJ; García O; Bargay J; Martínez-Robles V; Brunet S; Arilla MJ; Pérez de Oteyza J; Andreu R; Casaño FJ; Cervero CJ; Bailén A; Díez M; González B; Vicente AI; Pedro C; Bernal T; Luño E; Cedena MT; Palomera L; Simiele A; Calvo JM; Marco V; Gómez E; Gómez M; Gallardo D; Muñoz J; de Paz R; Grau J; Ribera JM; Benlloch LE; Sanz G
    Leuk Lymphoma; 2014 Jun; 55(6):1300-3. PubMed ID: 23952246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
    Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
    Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.
    Ye L; Ren Y; Zhou X; Mei C; Xu W; Ma L; Luo Y; Hu C; Ye X; Wei J; Lou Y; Jin J; Tong H
    Blood Cells Mol Dis; 2019 Jul; 77():88-94. PubMed ID: 31005752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
    Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.
    Prébet T; Gore SD; Esterni B; Gardin C; Itzykson R; Thepot S; Dreyfus F; Rauzy OB; Recher C; Adès L; Quesnel B; Beach CL; Fenaux P; Vey N
    J Clin Oncol; 2011 Aug; 29(24):3322-7. PubMed ID: 21788559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study
    Davidoff AJ; Hu X; Bewersdorf JP; Wang R; Podoltsev NA; Huntington SF; Gore SD; Ma X; Zeidan AM
    Leuk Lymphoma; 2020 May; 61(5):1178-1187. PubMed ID: 31878809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of azacitidine in myelodysplastic syndromes.
    Vigil CE; Martin-Santos T; Garcia-Manero G
    Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.